Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 38.3% in August

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 148,118 shares, a decline of 38.3% from the July 30th total of 240,225 shares. Based on an average daily volume of 159,888 shares, the short-interest ratio is currently 0.9 days. Currently, 0.0% of the shares of the stock are short sold.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Daiichi Sankyo presently has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

Daiichi Sankyo stock opened at $18.38 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The stock has a market cap of $34.24 billion, a price-to-earnings ratio of 21.37, a price-to-earnings-growth ratio of 2.52 and a beta of -0.18. The firm has a 50-day moving average of $17.04 and a two-hundred day moving average of $17.36. Daiichi Sankyo has a 1 year low of $14.98 and a 1 year high of $27.50.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, research analysts forecast that Daiichi Sankyo will post 0.97 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.